Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts.

Mesenchymal stromal cells (MSCs) are an essential cell type of the hematopoietic microenvironment. Concerns have been raised about the possibility that MSCs undergo malignant transformation. Several studies, including one from our own group, have shown the presence of cytogenetic abnormalities in MSCs from leukemia patients. The aim of the present study was to compare genetic aberrations in hematopoietic cells (HCs) and MSCs of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients. Cytogenetic aberrations were detected in HCs from 25 of 51 AML patients (49%) and 16 of 43 MDS patients (37%). Mutations of the FLT3 and NPM1 genes were detected in leukemic blasts in 12 (23%) and 8 (16%) AML patients, respectively. Chromosomal aberrations in MSCs were detected in 15 of 94 MDS/AML patients (16%). No chromosomal abnormalities were identified in MSCs of 36 healthy subjects. We demonstrate herein that MSCs have distinct genetic abnormalities compared with leukemic blasts. We also analyzed the main characteristics of patients with MSCs carrying chromosomal aberrations. In view of these data, the genetic alterations in MSCs may constitute a particular mechanism of leukemogenesis.

[1]  M. Brentani,et al.  Bone marrow stroma in childhood myelodysplastic syndrome: composition, ability to sustain hematopoiesis in vitro, and altered gene expression. , 2004, Leukemia research.

[2]  E. Thiel,et al.  Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations , 2006, Leukemia.

[3]  Zhe Wang,et al.  Cytogenetic analysis of human bone marrow‐derived mesenchymal stem cells passaged in vitro , 2007, Cell biology international.

[4]  M. Konopleva,et al.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[5]  H. Mayani,et al.  Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. , 2008, Leukemia research.

[6]  Xiuqing Guo,et al.  Loss of the Y chromosome: an age-related or clonal phenomenon in acute myelogenous leukemia/myelodysplastic syndrome? , 2009, Archives of pathology & laboratory medicine.

[7]  Martin Dugas,et al.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. , 2002 .

[8]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[9]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[10]  C. Mamalaki,et al.  Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. , 2010, Stem cells and development.

[11]  E. Estey.  High cytogenetic or molecular genetic risk acute myeloid leukemia. , 2010, Hematology. American Society of Hematology. Education Program.

[12]  S. Flamant,et al.  Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro , 2005, Oncogene.

[13]  C. Bloomfield,et al.  Cytogenetics in acute leukemia. , 2004, Blood reviews.

[14]  E. Thiel,et al.  Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. , 2007, Experimental hematology.

[15]  Brunangelo Falini,et al.  Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. , 2007, Blood.

[16]  E. Thiel,et al.  Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. , 2005, Experimental hematology.

[17]  Paolo Bernasconi,et al.  Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions–a review , 2008, British journal of haematology.

[18]  A. Cometa,et al.  Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms , 2010 .

[19]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[20]  W. Hiddemann,et al.  Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML , 2004, Leukemia.

[21]  S. Mundlos,et al.  Scientific Section: Myeloid Neoplasia; Hematopoiesis and Stem Cells Mesenchymal Stromal Cells of Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Have Distinct Genetic Abnormalities Compared with Leukemic Blasts Short Title: Genetic Anomalies in Mscs of Mds/aml Patients , 2022 .

[22]  C. Bloomfield,et al.  Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review , 2007, British journal of haematology.

[23]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[24]  J. Hernández-Rivas,et al.  Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q− syndrome , 2009, Leukemia.

[25]  K. Döhner,et al.  Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. , 2008, Seminars in oncology.

[26]  Charles P. Lin,et al.  Bone progenitor dysfunction induces myelodysplasia and secondary leukemia , 2010, Nature.

[27]  L. Shaffer,et al.  ISCN 2009 - An International System for Human Cytogenetic Nomenclature , 2009 .

[28]  S. Orkin,et al.  Rb Regulates Interactions between Hematopoietic Stem Cells and Their Bone Marrow Microenvironment , 2007, Cell.

[29]  M. Konopleva,et al.  Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins , 2002, Leukemia.

[30]  Stefan Fröhling,et al.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[31]  T. Haferlach,et al.  Molecular diagnostics in acute leukemias , 2009, Clinical chemistry and laboratory medicine.

[32]  Dirce M Carraro,et al.  Gene stage-specific expression in the microenvironment of pediatric myelodysplastic syndromes. , 2007, Leukemia research.

[33]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J J Shuster,et al.  Median follow-up in clinical trials. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Ramakrishnan,et al.  A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease , 2009, Expert opinion on biological therapy.

[36]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[37]  H. Mayani,et al.  Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. , 2005, Leukemia research.

[38]  P. Richardson,et al.  The malignant clone and the bone-marrow environment. , 2007, Best practice & research. Clinical haematology.